JP6265979B2 - チエノトリアゾロジアゼピン化合物を使用するリンパ腫の治療方法 - Google Patents

チエノトリアゾロジアゼピン化合物を使用するリンパ腫の治療方法 Download PDF

Info

Publication number
JP6265979B2
JP6265979B2 JP2015517810A JP2015517810A JP6265979B2 JP 6265979 B2 JP6265979 B2 JP 6265979B2 JP 2015517810 A JP2015517810 A JP 2015517810A JP 2015517810 A JP2015517810 A JP 2015517810A JP 6265979 B2 JP6265979 B2 JP 6265979B2
Authority
JP
Japan
Prior art keywords
cell
formula
lymphoma
compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015517810A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015531747A5 (https=
JP2015531747A (ja
Inventor
ベルトーニ，フランチェスコ
ボネッティ，パオラ
Original Assignee
オンコエシックス ゲーエムベーハー
オンコエシックス ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オンコエシックス ゲーエムベーハー, オンコエシックス ゲーエムベーハー filed Critical オンコエシックス ゲーエムベーハー
Publication of JP2015531747A publication Critical patent/JP2015531747A/ja
Publication of JP2015531747A5 publication Critical patent/JP2015531747A5/ja
Application granted granted Critical
Publication of JP6265979B2 publication Critical patent/JP6265979B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2015517810A 2012-06-25 2013-06-25 チエノトリアゾロジアゼピン化合物を使用するリンパ腫の治療方法 Expired - Fee Related JP6265979B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261663885P 2012-06-25 2012-06-25
US61/663,885 2012-06-25
US201261670918P 2012-07-12 2012-07-12
US61/670,918 2012-07-12
PCT/EP2013/063313 WO2014001356A1 (en) 2012-06-25 2013-06-25 Method of treating lymphoma using thienotriazolodiazepine compounds

Publications (3)

Publication Number Publication Date
JP2015531747A JP2015531747A (ja) 2015-11-05
JP2015531747A5 JP2015531747A5 (https=) 2016-07-28
JP6265979B2 true JP6265979B2 (ja) 2018-01-24

Family

ID=48672651

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015517810A Expired - Fee Related JP6265979B2 (ja) 2012-06-25 2013-06-25 チエノトリアゾロジアゼピン化合物を使用するリンパ腫の治療方法

Country Status (12)

Country Link
US (1) US20140018353A1 (https=)
EP (1) EP2863923B1 (https=)
JP (1) JP6265979B2 (https=)
KR (1) KR20150045423A (https=)
CN (1) CN105050605A (https=)
AU (1) AU2013283378B2 (https=)
BR (1) BR112014032105A2 (https=)
CA (1) CA2877434A1 (https=)
IN (1) IN2014DN11269A (https=)
MX (1) MX2014015986A (https=)
RU (1) RU2659171C2 (https=)
WO (1) WO2014001356A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016525563A (ja) * 2013-08-01 2016-08-25 オンコエシックス ゲーエムベーハー チエノトリアゾロジアゼピン化合物を含む医薬製剤

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102668696B1 (ko) 2012-01-12 2024-05-29 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
SG11201506924YA (en) 2013-03-15 2015-09-29 Incyte Corp Tricyclic heterocycles as bet protein inhibitors
EP3019502B1 (en) 2013-07-08 2017-05-17 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors
JP2016529246A (ja) * 2013-08-06 2016-09-23 オンコエシックス ゲーエムベーハー Ｂｅｔブロモドメイン阻害剤を用いるびまん性大細胞型ｂ細胞性リンパ腫（ｄｌｂｃｌ）の治療方法
WO2015018520A1 (en) * 2013-08-06 2015-02-12 Oncoethix Sa A bet-brd inhibitor represents a novel agent for alk positive anaplastic large cell lymphoma
WO2015018522A1 (en) * 2013-08-06 2015-02-12 Oncoethix Sa Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl)
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
WO2015081189A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
CN105960239A (zh) 2013-11-27 2016-09-21 翁科埃斯克斯有限公司 利用含有噻吩并三唑并二氮杂*化合物的药物制剂治疗白血病的方法
WO2015095492A1 (en) 2013-12-19 2015-06-25 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
PL3134403T3 (pl) 2014-04-23 2020-07-13 Incyte Corporation 1H-pirolo[2,3-c]pirydyn-7(6H)-ony i pirazolo[3,4-c]pirydyn-7(6H)-ony jako inhibitory białek BET
EP3137085A4 (en) 2014-05-02 2017-12-27 Oncoethix GmbH Method of treating acute myeloid leukemia and/or acute lymphoblastic leukemia using thienotriazolodiazepine compounds
US20170095484A1 (en) * 2014-05-02 2017-04-06 Oncoethix Gmbh Method of treating resistant non-hodgkin lymphoma, medulloblastoma, and/or alk+non-small cell lung cancer using thienotriazolodiazepine compounds
AU2015257658A1 (en) 2014-05-08 2016-11-10 Oncoethix Gmbh Method of treating triple-negative breast cancer using thienotriazolodiazepine compounds
BR112016029012A2 (pt) 2014-06-13 2017-08-22 Oncoethix Gmbh método de tratamento de câncer de pulmão de células não pequenas e/ou câncer de pulmão de células pequenas usando compostos de tienotriazolodiazepina
KR20170037670A (ko) 2014-08-19 2017-04-04 온코에틱스 게엠베하 티에노트리아졸로디아제핀 화합물을 사용한 림프종의 치료 방법
JP6599979B2 (ja) 2014-09-15 2019-10-30 インサイト・コーポレイション Ｂｅｔタンパク質阻害剤として用いるための三環式複素環化合物
KR101675984B1 (ko) * 2015-02-23 2016-11-14 한양대학교 에리카산학협력단 티에노디아제핀 유도체 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 포함하는 약학적 조성물
EP3270917A4 (en) 2015-03-18 2018-08-08 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
US10683305B2 (en) 2015-04-27 2020-06-16 Concert Pharmaceuticals, Inc. Deuterated OTX-015
EP3319944A4 (en) 2015-07-10 2019-04-24 Arvinas, Inc. MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS
US10772962B2 (en) 2015-08-19 2020-09-15 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
WO2017075377A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
US20170281784A1 (en) 2016-04-05 2017-10-05 Arvinas, Inc. Protein-protein interaction inducing technology
CA3028689A1 (en) 2016-06-20 2017-12-28 Incyte Corporation Crystalline solid forms of a bet inhibitor
IL312367A (en) 2017-01-31 2024-06-01 Arvinas Operations Inc Cereblon ligands and bifunctional compounds comprising the same
WO2019148055A1 (en) 2018-01-26 2019-08-01 Yale University Imide-based modulators of proteolysis and methods of use
CN108070562A (zh) * 2018-02-03 2018-05-25 金华市中心医院 一种“双打击”弥漫大b细胞淋巴瘤细胞系制备方法
IL302595A (en) 2018-04-13 2023-07-01 Arvinas Operations Inc Servalon ligands and bifunctional compounds containing them
WO2020055976A1 (en) * 2018-09-11 2020-03-19 Genentech, Inc. Tert-butyl (s)-2-(4-(phenyl)-6h-thieno[3,2-f][1,2,4]triazolo[4,3-a] [1,4]diazepin-6-yl) acetate derivatives and related compounds as bromodomain brd4 inhibitors for treating cancer
AU2020405129A1 (en) 2019-12-19 2022-06-23 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2025049555A1 (en) 2023-08-31 2025-03-06 Oerth Bio Llc Compositions and methods for targeted inhibition and degradation of proteins in an insect cell

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994006802A1 (fr) 1992-09-18 1994-03-31 Yoshitomi Pharmaceutical Industries, Ltd. Compose de thienodiazepine et son utilisation medicinale
CN1109037C (zh) * 1996-09-13 2003-05-21 三菱制药株式会社 噻吩并－三唑并二氮杂䓬化合物及其医药用途
KR101600634B1 (ko) * 2007-12-28 2016-03-07 미쓰비시 타나베 파마 코퍼레이션 항암제
JP5715241B2 (ja) * 2010-05-14 2015-05-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法
PL2902030T3 (pl) * 2010-05-14 2017-07-31 Dana-Farber Cancer Institute, Inc. Związki tienotriazolodiazepinowe do leczenia nowotworu
US10071129B2 (en) * 2011-08-30 2018-09-11 Whitehead Institute For Biomedical Research Dana-Farber Cancer Institute, Inc. Method for identifying bromodomain inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016525563A (ja) * 2013-08-01 2016-08-25 オンコエシックス ゲーエムベーハー チエノトリアゾロジアゼピン化合物を含む医薬製剤

Also Published As

Publication number Publication date
AU2013283378A1 (en) 2015-01-29
CN105050605A (zh) 2015-11-11
AU2013283378B2 (en) 2017-07-13
MX2014015986A (es) 2016-02-11
WO2014001356A1 (en) 2014-01-03
RU2015101106A (ru) 2016-08-10
EP2863923A1 (en) 2015-04-29
CA2877434A1 (en) 2014-01-03
IN2014DN11269A (https=) 2015-10-09
KR20150045423A (ko) 2015-04-28
EP2863923B1 (en) 2019-05-08
JP2015531747A (ja) 2015-11-05
BR112014032105A2 (pt) 2017-08-01
RU2659171C2 (ru) 2018-06-28
US20140018353A1 (en) 2014-01-16

Similar Documents

Publication Publication Date Title
JP6265979B2 (ja) チエノトリアゾロジアゼピン化合物を使用するリンパ腫の治療方法
Yan et al. Targeting autophagy to sensitive glioma to temozolomide treatment
Qin et al. CDK4/6 inhibitor palbociclib overcomes acquired resistance to third‐generation EGFR inhibitor osimertinib in non‐small cell lung cancer (NSCLC)
Costa et al. Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor
Lu et al. Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-κB signaling and depleting Bcr-Abl
Liu et al. Synergistic killing of lung cancer cells by cisplatin and radiation via autophagy and apoptosis
WO2019058348A1 (en) COMBINATION OF A BTK INHIBITOR AND A CDK9 INHIBITOR TO TREAT CANCER
Sajithlal et al. Sorafenib/regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells
Ren et al. Blockade efficacy of MEK/ERK-dependent autophagy enhances PI3K/Akt inhibitor NVP-BKM120's therapeutic effectiveness in lung cancer cells
Hussain et al. A novel PI3K axis selective molecule exhibits potent tumor inhibition in colorectal carcinogenesis
EP3866799A2 (en) Compositions and methods for treating vascular ehlers danlos syndrome and associated disorders
Valinciute et al. Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells
AU2014308700A1 (en) Cancer treatment
Lee et al. SPA0355, a thiourea analogue, inhibits inflammatory responses and joint destruction in fibroblast‐like synoviocytes and mice with collagen‐induced arthritis
McCubrey et al. OSU-03012 in the treatment of glioblastoma
RU2742033C2 (ru) Комбинации ингибиторов fgfr4 и секвестрантов желчных кислот
EP4110331B1 (en) Methods of treating dlbcl using btk inhibitors and combinations thereof
CN111163781A (zh) 用于治疗癌症的mdm2抑制剂与erk抑制剂的组合
Alejandra Pezuk et al. Polo-like kinase 1 pharmacological inhibition as monotherapy or in combination: comparative effects of polo-like kinase 1 inhibition in medulloblastoma cells
KR102436875B1 (ko) Pi3 키나아제 억제제 및 bcl-2 억제제를 포함하는 조성물
WO2015153866A1 (en) Cancer therapy with ganetespib and an egfr inhibitor
Zuo et al. Inhibition of Bromodomain-Containing 4 Sensitises Aggressive Non-Hodgkin Lymphomas to Phosphatidylinositol 3-Kinase δ Inhibitors
Cohen et al. A phase I study of HMPL-689, a selective oral phosphoinositide 3-kinase-delta inhibitor, in patients with relapsed or refractory lymphoma
WO2008116163A1 (en) Therapeutic drug combinations for treatment of b-cell malignancies
Boedicker Combined inhibition of BET proteins and PI3Kα reallocates BRD4 to transcriptional regulatory elements of BH3-only proteins and triggers mitochondrial apoptosis

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20160222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160222

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20160225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160602

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160602

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170214

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170810

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171205

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171219

R150 Certificate of patent or registration of utility model

Ref document number: 6265979

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees